Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-09-18
2007-09-18
Stockton, Laura L. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C548S309700, C548S315100, C548S338100, C514S394000, C514S397000, C514S399000
Reexamination Certificate
active
11168193
ABSTRACT:
Compounds are provided having the formula:wherein variables R0, R1, R2, R3, R4, Q, L and subscript n are as described herein. The subject compounds are useful for treatment of infammatory and immune conditions and diseases. Compositions and methods of treatment using the subject compounds are also provided. For example, the subject methods are useful for treatment of inflammatory and immune disorders and disease such as multiple sclerosis, rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
REFERENCES:
patent: 5719144 (1998-02-01), Hartman et al.
patent: 5756502 (1998-05-01), Padia
patent: 5869665 (1999-02-01), Padia
patent: 6140064 (2000-10-01), Loetscher et al.
patent: 6281237 (2001-08-01), Horvath et al.
patent: 6380210 (2002-04-01), DeSimone et al.
patent: 6545005 (2003-04-01), Baxter et al.
patent: 6605632 (2003-08-01), Lesieur et al.
patent: 6794379 (2004-09-01), Medina et al.
patent: 2002/0077329 (2002-06-01), Audoly et al.
patent: 2002/0169159 (2002-11-01), Medina et al.
patent: 2003/0055037 (2003-03-01), DeLombaert et al.
patent: 2003/0055054 (2003-03-01), Medina et al.
patent: 2003/0119854 (2003-06-01), Schall et al.
patent: 2003/0134843 (2003-07-01), Lubisch et al.
patent: 2003/0236260 (2003-12-01), Shimojo et al.
patent: 2004/0077662 (2004-04-01), Zhou et al.
patent: 2005/0075333 (2005-04-01), Medina et al.
patent: WO99/58495 (1995-11-01), None
patent: WO98/27108 (1998-06-01), None
patent: WO00/59888 (2000-10-01), None
patent: WO00/59905 (2000-10-01), None
patent: WO01/16114 (2001-03-01), None
patent: WO01/16114 (2001-03-01), None
patent: WO01/19800 (2001-03-01), None
patent: WO01/19800 (2001-03-01), None
patent: WO01/30768 (2001-05-01), None
patent: WO01/62758 (2001-08-01), None
patent: WO01/77087 (2001-10-01), None
patent: WO01/98278 (2001-12-01), None
patent: WO02/28831 (2002-04-01), None
patent: WO02/28839 (2002-04-01), None
patent: WO02/083143 (2002-10-01), None
patent: WO-03/047520 (2003-06-01), None
patent: WO03/076418 (2003-09-01), None
CA Registry No. 568560-83-8, indexed in the Registry file on STN on Aug. 18, 2003.
CA Registry No. 565178-07-6, indexed in the Registry file on STN on Aug. 12, 2003.
CA Registry No. 565171-54-2, indexed in the Registry file on STN on Aug. 12, 2003.
CA Registry No. 543744-05-4, indexed in the Registry file on STN on Jul. 7, 2003.
CA Registry No. 543743-61-9, indexed in the Registry file on STN on Jul. 7, 2003.
Maffrand et al., CA 82:125376, 1975.
Nakanishi et al., CA 81:136187, 1974.
Gerbert et al., CA 81:63944, 1974.
U.S. Appl. No. 11/168,005, filed Jun. 27, 2005, Fu et al.
U.S. Appl. No. 11/168,006, filed Jun. 27, 2005, Fu et al.
Balashov et al., 1999, “CCR5+and CXCR3+T Cells are Increased in Multiple Sclerosis and Their Ligands MIP-1α and IP-10 are Expressed in Demyelinating Brain Lesions,” Proc. Natl. Acad. Sci. USA, 96:6873-78.
Bowdish et al., 2003, “Evaluation of An Oral CXCR3 Antagonist in a Rat Model of the Acute Allograft Rejection,”The Journal of the Heart and Lung Associationvol. 22 Supplement 1 p. S162.
Carter, et al., 2002, “Chemokine Receptor Antagonism as an Approach to Anti-Inflammatory Therapy: ‘Just Right’ or Plain Wrong?”,Current Opin. Chem. Biol., 6: 510-525.
Fife et al., 2001, “CXCL10 (IFN-γ-Inducible Protein-10) Control of Encephalitogenic CD4+T Cell Accumulation in the Central Nervous System During Experimental Autoimmune Encephalomyelitis”,J. Immunol. 166: 7617-7624.
Gerard, et al., 2001, “Chemokines and Diseases”,Nature Immunology, 2(2): 108-115.
Goldberg et al., 2001, “CXCR3 Expression in Human Central Nervous System Diseases”, Neuropathol. Appl. Neurobiol. 27(2):127-38.
Hancock et al., 2000, “Requirement of the Chemokine Receptor CXCR3 for Acute Allograft Rejection,”J. Exp. Med., 192(10):1515-19.
Hancock et al., 2001, “ Donor-Derived IP-10 Initiates Development of Acute Allograft Rejection,”J. Exp. Med.193: 975-980.
Liu et al., 2001, “Neutralization of the Chemokine CXCL10 Reduces Inflammatory Cell Invasion and Demyelination and Improves Neurological Function in a Viral Model of Multiple Sclerosis”,J. Immunol. 167: 4091-4097.
Melter et al., 2001, “Expression of the Chemokine Receptor CXCR3 and Its Ligand IP-10 During Cardiac Allograft Rejection”,Circulation104: 2558-2564.
Onuffer, et al., 2002, “Chemokines, Chemokine Receptors and Small-Molecule Antagonists: Recent Developments”, Trends in Pharmacological Sciences 23(10): 459-467.
Padia, J.K., et al., “Design and synthesis of novel nonpeptide CCK-B receptor antagonists,” Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 7, No. 7, Apr. 8, 1997, pp. 805-810.
Proudfoot, et al., 2003, “Strategies for Chemokine Antagonists as Therapeutics”,Seminars in Immunology. 15:57-65.
Qin et al., 1998, “The Chemokine Receptors CXCR3 and CCR5 Mark Subsets of T Cells Associated with Certain Inflammatory Reactions,”J. Clin. Invest. 101(4): 746-54.
Rabin et al., 1999, “Chemokine Receptor Responses on T Cells Achieved Through Regulation of Both Receptor Expression and Signaling,”The Journal of Immunology, 162: 3840-50.
Rottman et al., 2001, “Potential Role of the Chemokine Receptors CXCR3, CCR4, and the Integrin αEβ7 in the Pathogenesis ofPsoriasis vulgaris”, Lab. Invest. 81(3): 335-347.
Ruschpler et al., 2003, “Hign CXCR3 Expression in nSynovial Mast Cells Associated with CXCL9 and CXCL10 Expression in Inflammatory Synovial Tissues of Patients with Rheumatoid Arthritis”,Arthritis Res. Ther. 5: R241-R252.
Sasaki et al., Nov. 2002, “Blockade of CXCL10 Protects Mice From Acute Colitis and Enhances Crypt Cell Survival”,Eur. J. Immunol. 32: 3197-31205.
Sorensen et al., 1999, “Expression of Specific Chemokines and Chemokine Receptors in the Central Nervous System of Multiple Sclerosis Patients”,J. Clinical Invest. 103: 807-815.
Wells, et al., 1999, “Chemokine Receptors and Their Antagonists in Allergic Lung Disease”Inflamm. Res., 48: 353-362.
International Search Report for PCT/US2005/023274, Dec. 23, 2005, PCT.
Bergeron Philippe
Chen Xiaoqi
Deignan Jeffrey
Du Xiaohui
Duquette Jason A.
Amgen SF, LLC
Jones Day
Stockton Laura L.
LandOfFree
Imidazolo-related compounds, compositions and methods for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazolo-related compounds, compositions and methods for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazolo-related compounds, compositions and methods for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3754034